The dependence of successful immunotherapy on adequate tumor burden as shown by the treatment of AKR leukemia with poly A-poly U.

Abstract

The therapeutic efficacy of polyadenlyic-polyuridylic acid (poly A-poly U) on the transplantable AKR leukemia varied with the dose of tumor cells implanted. The greater the number of AKR tumor cells injected into 8-week-old AKR mice free of clinical evidence of cancer, the greater the effect of poly A-poly U in mediating host immunologic control of the tumor. Poly A-poly U was either ineffective or could enhance tumor growth when smaller doses of tumor cells were transferred. The efficacy of an immune adjuvant depended on a tumor burden affording optimum host responsiveness. This does not necessarily arise in the host bearing minimal tumor burden.

• Authors: W J Pendergrast Jr, W P Drake, M R Mardiney Jr
• Journal: Journal of the National Cancer Institute (J Natl Cancer Inst) Vol. 55 Issue 5 Pg. 1223-5 (Nov 1975) ISSN: 0027-8874 [Print] United States
• PMID: 1206751 (Publication Type: Journal Article)

Chemical References

• Adjuvants, Immunologic
• Antigens, Neoplasm
• Poly A-U

Topics

• Adjuvants, Immunologic
• Animals
• Antigens, Neoplasm
• Immunotherapy
• Leukemia, Experimental (immunology, therapy)
• Mice
• Mice, Inbred AKR
• Poly A-U (therapeutic use)